Valion Bio (VBIO) Share-based Compensation (2021 - 2026)
Valion Bio (VBIO) posted Share-based Compensation of $356002.0 for Q2 2026, up 138.93% on a QoQ basis from $149000.0 in Q4 2025, and down 30.42% year-over-year from $511669.0 in Q2 2025.
Powered by 
Analysis
Valion Bio (VBIO) Share-based Compensation (2021 - 2026) Analysis & Trends
Valion Bio has reported Share-based Compensation for 6 years, with the latest figure at $356002.0 in Q2 2026.
- On a quarterly basis, Share-based Compensation fell 30.42% year-over-year to $356002.0 in Q2 2026; TTM through Jun 2026 was $356002.0, a 30.42% decrease from a year earlier, with the FY2025 full-year figure at $974000.0, up 325.33% from the prior year.
- Share-based Compensation was $356002.0 for Q2 2026 at Valion Bio, up from $149000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $1.1 million in Q1 2022, with the low at $48000.0 in Q3 2023.
- Average Share-based Compensation over 5 years is $197647.5, with a median of $100000.0 recorded in 2025.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation soared 1300.0% in 2022, then tumbled 92.01% in 2023.
- Over 5 years, Share-based Compensation stood at $112000.0 in 2022, then slumped by 48.21% to $58000.0 in 2023, then rose by 8.62% to $63000.0 in 2024, then soared by 136.51% to $149000.0 in 2025, then surged by 138.93% to $356002.0 in 2026.
- The last three Share-based Compensation figures came in at $356002.0 (Q2 2026), $149000.0 (Q4 2025), and $355368.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 83.34 Mn |
| 10 | Valion Bio | 298,792.01 | -1.90 Mn | -45,000.00 | 356,002.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 356,002.00 |
| Dec 31, 2025 | 149,000.00 |
| Sep 30, 2025 | 355,368.00 |
| Jun 30, 2025 | 511,669.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 63,000.00 |
| Sep 30, 2024 | 58,000.00 |
| Jun 30, 2024 | 54,000.00 |
| Mar 31, 2024 | 54,000.00 |
| Dec 31, 2023 | 58,000.00 |
| Sep 30, 2023 | 48,000.00 |
| Jun 30, 2023 | 81,000.00 |
| Mar 31, 2023 | 84,000.00 |
| Dec 31, 2022 | 112,000.00 |
| Sep 30, 2022 | 113,000.00 |
| Jun 30, 2022 | 112,000.00 |
| Mar 31, 2022 | 1.05 Mn |
| Dec 31, 2021 | 239,000.00 |
| Sep 30, 2021 | 23,000.00 |
| Jun 30, 2021 | 8,000.00 |